Navigation Links
Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
Date:5/28/2009

- Phase II clinical trial investigating the effectiveness of Intercell's Vaccine Enhancement (VE) Patch in combination with an injectable H5N1 pandemic influenza vaccine started today in the U.S.

- The study is fully funded by HHS - this is the second study conducted under a 5 year USD 128 m contract with the HHS

- Intercell's VE Patch may reduce the dosage and improve protection against an H5N1 pandemic influenza outbreak with only a single dose vaccine application

VIENNA and GAITHERSBURG, Md., May 28 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that it has advanced its efforts to develop its VE Patch to improve prevention of H5N1 pandemic influenza with the start of a Phase II clinical trial. The randomized and blinded study aims to determine the optimal dosage of both Intercell's VE Patch and the H5N1 influenza vaccine injected concomitantly, when combined with each other in a single dose regimen. The trial will be conducted in the U.S. and is expected to enroll 500 subjects at six study sites.

"The commencement of this Phase II study represents an important milestone in the clinical development of our VE Patch technology and in the partnership with HHS for use of our technology in providing potentially improved Pandemic Influenza vaccines," stated Thomas Lingelbach, COO of Intercell AG and CEO of Intercell USA. "The recent H1N1 influenza situation certainly highlights again the important global public health need in this arena. If we achieve our goal to achieve full protection with only a single dose plus patch this means an enormous logistical advantage making PanFlu immunization feasible."

The H5N1 pandemic influenza vaccine tested in the study comprises Intercell's VE Patch and an injectable H5N1 influenza vaccine manufactured by Solvay Biologicals, B.V. (Netherlands).

In 2008 Intercell announced the results of a first clinical trial wher
'/>"/>

SOURCE Intercell AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
2. Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers Diarrhea Vaccine Study
3. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
4. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
5. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
6. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
7. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
8. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
9. Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
10. Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R)
11. Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014  Dr. Stephen Loyd , ... House today for National Recovery Month, stars in a ... released today. Consumer advocates were also joined by a ... out after losing her fiancée because of a preventable ... had a history of crack cocaine abuse. Proposition 46 ...
(Date:9/17/2014)... , Sept. 17, 2014  Decision Resources ... (CD/UC) patients eligible for biologic therapy, only ... biologic. Surveyed gastroenterologists cite patients, discomfort with ... low penetration rates, followed by cost-related issues ... patients receiving biologics, Janssen Biotech,s Remicade and ...
(Date:9/17/2014)... Inc. announced this morning that results of the Phase 2 ... will be presented in two posters and a podium presentation ... from October 8-12. PUNCH CD study ... October 9, 2014: Poster: RBX2660 (microbiota suspension) for ... the PUNCH-CD Phase 2 Safety Study , ...
Breaking Medicine Technology:Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4
(Date:9/17/2014)... 17, 2014 People who struggle to distinguish ... to http://www.perwickstrom.com and get the answer by reading ... point out, is that a business plan and a business ... together, commented Per Wickstrom. “The way I view it is ... business strategy which is part two.” , According to ...
(Date:9/17/2014)... 2014 (HealthDay News) -- Social networking sites can help ... For people who are obese, sites like Twitter and ... support from doctors as well as peers, researchers found. ... methods is that it offers the potential to be ... when compared to traditional approaches," the study,s lead author, ...
(Date:9/17/2014)... Bioluminescence, nanoparticles, gene manipulation these sound like ... in fact, they are components of an exciting ... In preclinical animal models of metastatic prostate cancer, ... VCU Institute of Molecular Medicine and Johns Hopkins ... molecular imaging approach that could revolutionize doctors, ability ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 North Central ... recently granted several awards for their top-notch services. The ... experience, orthopedic care and GYN surgery. , Hospital-wide, North ... Excellence Award™. They have received this award for two ... the top 5 percent in the nation for Patient ...
(Date:9/17/2014)... 2014 Catalent Pharma Solutions, the ... development solutions for drugs, biologics and consumer health ... integrated service and technology offer based on the ... the company’s 450,000 sq. ft. Kansas City, MO ... integrate optimal formulation, development, analytical expertise, scale up ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:Social Networking Sites Can Help Obese Lose Weight: Study 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:North Central Surgical Center Receives Several Accolades 2Health News:New OptiPact™ Technology Introduced by Catalent 2
... ... virtual reality device, the GaitAid, can help stroke patients learn to walk better. , ... Haifa, Israel (PRWEB) February 22, 2010 -- There are ... one of the leading causes of adult disability in the U.S. and Europe., , , , ...
... new survey has found that African-Americans are more likely ... lung cancer, as well as being more reluctant to ... according to researchers from Dana-Farber Cancer Institute and their ... the puzzling racial disparities in lung cancer treatment outcomes ...
... outlets for buying booze increases, so does neighborhood violence, ... The more bars, restaurants and other alcohol sales sites ... say researchers who studied crime statistics and alcohol licensing ... found an association between high assault rates and stores ...
... three million children have been born as a result of ... tube baby" in 1978. While the majority of these ... at greater risk of certain kinds of birth defects and ... and type 2 diabetes later in life. Carmen Sapienza, ...
... types of minimally invasive surgery to repair kidney blockages ... found that robot-assisted surgery was faster and resulted in ... in the Canadian Journal of Urology , Ashok ... Baptist Medical Center, compared laparoscopic and robot-assisted surgery for ...
... 20. "Nanotechnology could aid the future of development of the ... the academy of sciences for the developing world, and president ... at a panel session, "Re-emergence of Science, Technology and Education ... AAAS,s annual meeting in San Diego. "The Arab ...
Cached Medicine News:Health News:New Successful Treatment Improves Walking Post Stroke 2Health News:African-Americans' attitudes about lung cancer may hinder prevention 2Health News:More Bars Equals More Assaults, Study Finds 2Health News:Comparison shows robot-assisted option offers advantages for kidney surgery 2Health News:Nanotechnology could help Arab region 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: